Liquid chromatographic enantioseparation of thalidomide and its derivatives on cyclodextrin-bonded stationary phases

1. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol. 2001; 57(5):365-376.10.1007/s002280100320Search in Google Scholar

2. Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol. 2007; 39(7-8):1489-1499.1736907610.1016/j.biocel.2007.01.022Search in Google Scholar

3. Ridings JE. The thalidomide disaster, lessons from the past. Methods Mol Biol. 2013; 947:575-586.10.1007/978-1-62703-131-8_36Search in Google Scholar

4. Eriksson T, Bjorkman S, Roth B, Hoglund P. Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J Pharm Pharmacol. 2000; 52(7):807-817.10.1211/002235700177466010933131Open DOISearch in Google Scholar

5. Höglund P, Eriksson T, Björkman S. A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J Pharmacokinet and Biopharm. 1998; 26(4):363-383.1021455810.1023/A:1021008016719Search in Google Scholar

6. Nishimura K, Hashimoto Y, Iwasaki S. (S)-form of alpha-methyl-N(α)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects. Chem Pharm Bull. 1994; 42(5):1157-1159.10.1248/cpb.42.11578069968Open DOISearch in Google Scholar

7. Wnendt S, Finkam M, Winter W, Ossig J, Raabe G, Zwingenberger K. Enantioselective inhibition of TNF-α release by thalidomide and thalidomide-analogues. Chirality. 1996; 8(5):390-396.10.1002/(SICI)1520-636X(1996)8:5<390::AID-CHIR6>3.0.CO;2-IOpen DOISearch in Google Scholar

8. Tian C, Xiu P, Meng Y, Zhao W, Wang Z, Zhou R. Enantiomerization mechanism of thalidomide and the role of water and hydroxide ions. Chemistry. 2012 5; 18(45):14305-14313.10.1002/chem.201202651Search in Google Scholar

9. Wolf C. Dynamic stereochemistry of chiral compounds: principles and applications: RSC Publishing; 2008. p. 29-135.Search in Google Scholar

10. Sheskin J. Thalidomide in the Treatment of Lepra Reactions. Clin Pharmacol Ther. 1965; 6:303-306.1429602710.1002/cpt196563303Search in Google Scholar

11. Licht JD, Shortt J, Johnstone R. From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma. Cancer Cell. 2014; 25(1):9-11.10.1016/j.ccr.2013.12.019Open DOISearch in Google Scholar

12. Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol. 2005; 32(4 Suppl 5): S24-30.10.1053/j.seminoncol.2005.06.01816085014Open DOISearch in Google Scholar

13. Łączkowski KZ, Baranowska-Łączkowska A. Recent studies on the thalidomide and its derivatives. Future Med Chem. 2018; 10(18) 2133-2136.10.4155/fmc-2018-021730088422Search in Google Scholar

14. Jacques V, Czarnik AW, Judge TM, Van der Ploeg LH, DeWitt SH. Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs. Proc Natl Acad Sci USA. 2015; 112(12):E1471-1479.10.1073/pnas.1417832112437838825775521Search in Google Scholar

15. Uttamsingh V, Gallegos R, Cheng C, Aslanian A, Liu JF, Tung R, Wu L. CTP-221, a deuterated S-enantiomer of lenalidomide, is greatly stabilized to epimerization and results in a more desirable pharmacokinetic profile than racemic lenalidomide. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3357. doi:10.1158/1538-7445.AM2013-3357 AACR; 2013.10.1158/1538-7445.AM2013-3357Search in Google Scholar

16. Wu L, Aslanian AM, Liu JF, Hogan K, Tung R. CTP-221, a Deuterated S-Enantiomer of Lenalidomide, Possesses Significantly Enhanced Immunomodulatory and Anti-Proliferative Properties Relative to the R-Enantiomer and to Racemic Lenalidomide. Blood 2012, 120:2463.10.1182/blood.V120.21.2463.2463Search in Google Scholar

17. Chung F, Palmer BD, Muller GW, Man HW, Kestell P, Baguley BC, et al. Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Oncol Res. 2003; 14(2):75-82.10.3727/00000000310874862114649541Open DOISearch in Google Scholar

18. Knabe J, Omlor G. [Synthesis of racemates and enantiomers of 3-alkylthalidomide analogs and determination of their absolute configuration]. Arch Pharm (Weinheim). 1989; 322(8):499-505.10.1002/ardp.198932208092604538Search in Google Scholar

19. Szabo ZI, Foroughbakhshfasaei M, Gal R, Horvath P, Komjati B, Noszal B, Tóth G. Chiral separation of lenalidomide by liquid chromatography on polysaccharide-type stationary phases and by capillary electrophoresis using cyclodextrin selectors. J Sep Sci. 2018; 41(6):1414-1423.10.1002/jssc.20170121129211341Open DOISearch in Google Scholar

20. Szabo ZI, Szocs L, Horvath P, Komjati B, Nagy J, Janoska A, Noszal B., Toth G. Liquid chromatography with mass spectrometry enantioseparation of pomalidomide on cyclodextrin-bonded chiral stationary phases and the elucidation of the chiral recognition mechanisms by NMR spectroscopy and molecular modeling. J Sep Sci. 2016; 39(15):2941-2949.10.1002/jssc.20160035427279456Search in Google Scholar

21. Szabó ZI, Mohammadhassan F, Szőcs L, Nagy J, Komjáti B, Noszál B, Toth G. Stereoselective interactions and liquid chromatographic enantioseparation of thalidomide on cyclodextrin-bonded stationary phases. J Incl Phenom Macrocycl Chem. 2016; 85(3-4):227-236.10.1007/s10847-016-0622-3Search in Google Scholar

22. Del Valle EM. Cyclodextrins and their uses: a review. Process Biochem. 2004; 39(9):1033-1046.10.1016/S0032-9592(03)00258-9Open DOISearch in Google Scholar

23. Szabo ZI, Toth G, Volgyi G, Komjati B, Hancu G, Szente L, Beni S, Muntean DL, Noszal B. Chiral separation of asenapine enantiomers by capillary electrophoresis and characterization of cyclodextrin complexes by NMR spectroscopy, mass spectrometry and molecular modeling. J Pharm Biomed Anal. 2016; 5(117):398-404.10.1016/j.jpba.2015.09.022Search in Google Scholar

24. Szejtli J. Cyclodextrin inclusion complexes. Cyclodextrin technology: Springer; 1988. p. 79-185.10.1007/978-94-015-7797-7_2Search in Google Scholar

25. Tóth G, Mohácsi R, Rácz Á, Rusu A, Horváth P, Szente L, Béni Sz, Noszál B. Equilibrium and structural characterization of ofloxacin–cyclodextrin complexation. J Incl Phenom Macrocycl Chem. 2013; 77(1-4):291-300.10.1007/s10847-012-0245-2Search in Google Scholar

26. Armstrong DW, DeMond W. Cyclodextrin bonded phases for the liquid chromatographic separation of optical, geometrical, and structural isomers. J Chrom Sci. 1984; 22(9):411-415.10.1093/chromsci/22.9.411Search in Google Scholar

27. Kawaguchi Y, Tanaka M, Nakae M, Funazo K, Shono T. Chemically bonded cyclodextrin stationary phases for liquid chromatographic separation of aromatic compounds. Anal Chem. 1983; 55(12):1852-1857.10.1021/ac00262a005Search in Google Scholar

28. Hinze WL, Riehl TE, Armstrong DW, DeMond W, Alak A, Ward T. Liquid chromatographic separation of enantiomers using a chiral β-cyclodextrin-bonded stationary phase and conventional aqueous-organic mobile phases. Anal Chem. 1985;57(1):237-242.10.1021/ac00279a055Search in Google Scholar

29. GuangáLan W, KayáChee K, KeongáWong M, KeeáLee H, MináSin Y. Orthogonal array design as a chemometric method for the optimization of analytical procedures. Part 4. Mixed-level design and its application to the high-performance liquid chromatographic determination of polycyclic aromatic hydrocarbons. Analyst. 1995; 120(2):281-287.10.1039/an9952000281Search in Google Scholar

30. Neumajer G, Sohajda T, Darcsi A, Toth G, Szente L, Noszal B, Béni Sz Chiral recognition of dapoxetine enantiomers with methylated-gamma-cyclodextrin: a validated capillary electrophoresis method. J Pharm Biomed Anal.. 2012; 62:42-47.Search in Google Scholar

31. Wan HB, Lan WG, Wong MK, Mok CY. Orthogonal array designs for the optimization of liquid chromatographic analysis of pesticides. Anal Chim Acta. 1994; 289(3):371-380.10.1016/0003-2670(94)90014-2Search in Google Scholar